Clinical trials: Candidiasis
Candidiasis, Invasive, Candidemia
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida…
- Trial name
- CARES (NCT03363841)
- Testing
- SCY-078
- Where
- 12 sites in United States, India and 2 more
- Volunteers
- 30 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
This is an open-label, single-armed, multi-center study to evaluate clinical performance, tolerability, and safety of Gedea Pessary in 24 adult women with vulvovaginal candidias (VVC).
- Trial name
- NCT03761628
- Testing
- pHyph generation I
- Where
- 2 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- Gedea Biotech AB
Vulvovaginal Candidiasis
Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
This is a multi-centre, multi-national study to evaluate the clinical performance and safety of treatment with Gedea Pessary in adult women with confirmed vulvovaginal candidiasis (VVC).
- Trial name
- EpHect (NCT05507333)
- Testing
- pHyph generation II
- Where
- 4 sites in Sweden
- Volunteers
- 26 people
- Sponsor
- Gedea Biotech AB
Aspergillus Infections, Candida Infections
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
- Conditions
- Aspergillus Infections, Candida Infections, Fungal Infections
- Trial name
- NCT02631954
- Testing
- Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Systemic Mycosis
Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety informations of voriconazole related to their appropriate use in daily practice.
- Trial name
- NCT01151085
- Testing
- Voriconazole
- Volunteers
- 1,002 people
- Sponsor
- Pfizer
Candidiasis, Vaginosis, Bacterial
Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
The purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference…
- Trial name
- DOBO (NCT02860845)
- Testing
- Boric acid and probiotics, Antibiotic (Clindamycin), Antifungal (Clotrimazole)
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Laboratorios Ordesa
Invasive Candidiasis
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)
- Trial name
- NCT00250432
- Testing
- caspofungin acetate
- Volunteers
- 204 people
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcal Infections, Yeast Infections
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
This partially-blind, placebo controlled study is a Phase 1b study using an investigational vaccine, NDV-3, directed against Staphylococcus aureus and Candida sp.
- Conditions
- Staphylococcal Infections, Yeast Infections, Candidiasis
- Trial name
- NCT01447407
- Testing
- NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, NDV-3 vaccine without alum ID
- Where
- United States
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Candidemia
A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis
In the treatment of patients with candidemia and/or other forms of invasive candidiasis , Anidulafungin is at least as effective and safe as Fluconazole.
- Trial name
- NCT01176058
- Testing
- Anidulafungin/Fluconazole
- Where
- 7 sites in China
- Volunteers
- 17 people
- Sponsor
- Pfizer
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03561701)
- Testing
- Oteseconazole (VT-1161)
- Where
- 14 sites in United States
- Volunteers
- 425 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Candidemia
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
This is a multicenter, open-label, non-comparative, single-arm study to evaluate the efficacy and safety of APX001 for the first-line treatment for candidemia including suspected or confirmed antifungal-resistant candidemia in…
- Trial name
- NCT03604705
- Testing
- APX001
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Candidiasis
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.
- Trial name
- NCT01092832
- Testing
- voriconazole
- Where
- 14 sites in China, Czechia and 6 more
- Volunteers
- 23 people
- Sponsor
- Pfizer
Vulvovaginal Candidiasis
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of…
- Trial name
- NCT00803738
- Testing
- Terconazole Vaginal Suppository, Terazol Vaginal Suppository
- Volunteers
- 572 people
- Sponsor
- Padagis LLC
Candidemia, Invasive Candidiases
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C.
- Conditions
- Candidemia, Invasive Candidiases, Candida Infection
- Trial name
- APEX (NCT04148287)
- Testing
- APX001
- Where
- 2 sites in South Africa
- Volunteers
- 9 people
- Sponsor
- Basilea Pharmaceutica
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Candidiasis
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
- Trial name
- MAGIC-2 (NCT00815516)
- Testing
- micafungin, amphotericin B deoxycholate
- Where
- 17 sites in United States, Brazil and 10 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Candidemia, Mycoses
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Trial name
- ReSTORE (NCT03667690)
- Testing
- Rezafungin for Injection, Caspofungin, Fluconazole
- Where
- 132 sites in United States, Argentina and 16 more
- Volunteers
- 199 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Candidiasis, Candidemia
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT00739934
- Testing
- voriconazole (Vfend)
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Candida Vulvovaginitis
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and…
- Trial name
- DOVE (NCT03253094)
- Testing
- Fluconazole, SCY-078
- Where
- 25 sites in United States
- Volunteers
- 186 people
- Sponsor
- Scynexis, Inc.